numares AG, a Regensburg, Germany-based provider of innovative in-vitro diagnostic systems, completed a €2m financing round.
Backers included Wachstumsfonds Bayern (Bayern Capital).
The company intends to use the funds to expand its development pipeline continue its international expansion.
Led by Dr. Volker Pfahlert, Executive President, numares develops and markets integrated test systems for human diagnostics based on nuclear magnetic resonance spectroscopy (NMR). The diagnostic tests interpret patients’ individual metabolism profiles using proprietary MGS technology. The results of these tests provide insights into the origin, extent and seriousness of diseases.
The company currently employs about 50 people.